ACHP submitted comments to HHS/Department of the Treasury/Department of Labor on the tri-agency’s request for information on the Prescription Drug Machine-Readable File Requirement in the Transparency in Coverage Final Rule.
ACHP strongly supports the inclusion of Medicare Part B drugs and the renegotiation of previously selected drugs from 2026 and 2027.
ACHP calls on policymakers to consider the Three Cs (coverage, clinical flexibility and competition) to ensure the right patients are receiving the right drugs at the right time.
ACHP calls on Congress to increase access to biosimilars by redefining interchangeability requirements and addressing outdated regulations, skewed incentives and PBM practices that intentionally slow their adoption.
ACHP calls on policymakers to restore accountability to the FDA’s Accelerated Approval Pathway so effective therapies can reach patients facing serious, life-threatening diseases.
